| Naslov: | Effectiveness of baricitinib in severe alopecia areata in real life : an retrospective study of 87 patients |
|---|
| Avtorji: | ID Aleid, Nouf M. (Avtor) |
|---|
| Datoteke: |  PDF - Predstavitvena datoteka, prenos (665,64 KB)
MD5: 13B196954BB221FE6722D991B39F2B85
 URL - Izvorni URL, za dostop obiščite https://acta-apa.mf.uni-lj.si/journals/acta-dermatovenerol-apa/papers/10.15570/actaapa.2025.33/actaapa.2025.33.pdf
|
|---|
| Jezik: | Angleški jezik |
|---|
| Tipologija: | 1.01 - Izvirni znanstveni članek |
|---|
| Organizacija: |  ZSD - Združenje slovenskih dermatovenerologov
|
|---|
| Povzetek: | Introduction: Alopecia areata (AA) is an autoimmune condition characterized by non-scarring hair loss. The Janus kinase (JAK)signal transducer and activator of transcription (STAT) pathway is believed to play a central role in the autoimmune inflammatory processes underlying AA. Baricitinib, an oral JAK inhibitor, has been approved by the Food and Drug Administration (FDA) for the treatment of severe AA. This study evaluates the efficacy and safety of baricitinib in the management of AA. Methods: A retrospective cohort study was conducted on patients with AA receiving baricitinib 4 mg daily and that had completed a 1-year follow-up. Disease severity was assessed at baseline and the end of follow-up using the Severity of Alopecia Tool (SALT) score. Adverse events were systematically recorded. Results: Among 87 patients included in the analysis, the mean age was 29.84 years, and the mean baseline SALT score was 77.07%. After a mean of 52 weeks, 37.20% of patients achieved a SALT score ≤ 20. A significant reduction in SALT scores was observed at the end of follow-up (p < 0.001). In addition, 72.40% of patients experienced mild or no adverse events, and no serious adverse events were reported. Conclusions: In this 52-week real-world cohort, baricitinib demonstrated both effectiveness and good tolerability in the treatment of severe AA. These findings contribute to the understanding of long-term outcomes with baricitinib therapy. |
|---|
| Ključne besede: | alopecia areata, baricitinib, efficacy, Janus kinase inhibitors, safety |
|---|
| Status publikacije: | Objavljeno |
|---|
| Verzija publikacije: | Objavljena publikacija |
|---|
| Poslano v recenzijo: | 08.08.2025 |
|---|
| Datum sprejetja članka: | 04.11.2025 |
|---|
| Datum objave: | 01.12.2025 |
|---|
| Kraj izida: | Ljubljana |
|---|
| Založnik: | Združenje slovenskih dermatovenerologov |
|---|
| Leto izida: | 2025 |
|---|
| Št. strani: | str. 183-186 |
|---|
| Številčenje: | Vol. 34, issue 4 |
|---|
| PID: | 20.500.12556/DiRROS-29914  |
|---|
| UDK: | 616.594.1 |
|---|
| ISSN pri članku: | 1318-4458 |
|---|
| DOI: | 10.15570/actaapa.2025.33 |
|---|
| COBISS.SI-ID: | 276703491 |
|---|
| Avtorske pravice: | Na spletni strani revije navedeno: Acta Dermatovenerologica Alpina, Pannonica et Adriatica (ISSN 1318-4458) is an open access medical journal published quarterly by the Association of Slovenian Dermatovenerologists (https://acta-apa.mf.uni-lj.si/index.php); Authors publishing in our journal retain copyright of their work under the Creative Commons Attribution License (CC BY 4.0). This license allows unrestricted use, distribution, and reproduction of the work in any medium, provided the original author(s) and copyright holder(s) are appropriately credited, and the original publication in the journal is properly cited, following established academic practices (https://acta-apa.mf.uni-lj.si/submissions.php). |
|---|
| Datum objave v DiRROS: | 15.06.2026 |
|---|
| Število ogledov: | 222 |
|---|
| Število prenosov: | 137 |
|---|
| Metapodatki: |    |
|---|
|
:
|
Kopiraj citat |
|---|
| | | | Objavi na: |  |
|---|
Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše
podrobnosti ali sproži prenos. |
